BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahmed M. Era of direct acting anti-viral agents for the treatment of hepatitis C. World J Hepatol 2018; 10(10): 670-684 [PMID: 30386460 DOI: 10.4254/wjh.v10.i10.670] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Emam A, Abdellatif KRA, Amin NH, Elokely KM. HCV NS5B RdRp mutations and their effects on ligand binding affinity. International Journal of Modelling and Simulation. [DOI: 10.1080/02286203.2021.1923953] [Reference Citation Analysis]
2 Gwathmey KG, Tracy JA, Dyck PJB. Peripheral Nerve Vasculitis. Neurologic Clinics 2019;37:303-33. [DOI: 10.1016/j.ncl.2019.01.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
3 Keikha M, Eslami M, Yousefi B, Ali-Hassanzadeh M, Kamali A, Yousefi M, Karbalaei M. HCV genotypes and their determinative role in hepatitis C treatment. Virusdisease 2020;31:235-40. [PMID: 32904762 DOI: 10.1007/s13337-020-00592-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Williams-Nguyen J, Hawes SE, Nance RM, Lindström S, Heckbert SR, Kim HN, Mathews WC, Cachay ER, Budoff M, Hurt CB, Hunt PW, Geng E, Moore RD, Mugavero MJ, Peter I, Kitahata MM, Saag MS, Crane HM, Delaney JA. Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United States. Am J Epidemiol 2020;189:554-63. [PMID: 31712804 DOI: 10.1093/aje/kwz236] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Gao Y, Nepal N, Jin SZ. Toll-like receptors and hepatitis C virus infection. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00155-7. [PMID: 34419367 DOI: 10.1016/j.hbpd.2021.07.011] [Reference Citation Analysis]
6 Boff da Costa R, Boff Costa M, Longo L, Miotto DE, Hirata Dellavia G, Trucollo Michalczuk M, Reis Álvares-da-Silva M. Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications. PLoS One 2021;16:e0245767. [PMID: 33577593 DOI: 10.1371/journal.pone.0245767] [Reference Citation Analysis]
7 Liu L, Zhang M, Hang L, Kong F, Yan H, Zhang Y, Feng X, Gao Y, Wang C, Ma H, Liu X, Zhan M, Pan Y, Xu H, Niu J. Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection. Virol J 2020;17:14. [PMID: 32005264 DOI: 10.1186/s12985-020-1293-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Cuypers L, Thijssen M, Shakibzadeh A, Deboutte W, Sarvari J, Sabahi F, Ravanshad M, Pourkarim MR. Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran. Infect Genet Evol 2019;75:103966. [PMID: 31323326 DOI: 10.1016/j.meegid.2019.103966] [Reference Citation Analysis]
9 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
10 Hashimoto Y, Okada Y, Shirakura K, Tachibana K, Sawada M, Yagi K, Doi T, Kondoh M. Anti-Claudin Antibodies as a Concept for Development of Claudin-Directed Drugs. J Pharmacol Exp Ther 2019;368:179-86. [DOI: 10.1124/jpet.118.252361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Huffman V, Andrade DC, Sherman E, Niu J, Eckardt PA. Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection. Am J Health Syst Pharm 2021;78:36-40. [PMID: 33037429 DOI: 10.1093/ajhp/zxaa328] [Reference Citation Analysis]
12 Gupta E, Choudhary MC, Upadhyay N, Singh G, Nayak SL, Kumar M, Sarin SK. Lower Rates Of Naturally Occurring Resistance-Associated Substitutions (RASs) In Hepatitis C Virus (HCV)-Infected Chronic Kidney Disease (CKD) Patients Than In HCV-Infected Patients With Only Liver Disease. Infect Drug Resist 2019;12:3635-40. [PMID: 31819546 DOI: 10.2147/IDR.S220335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]